Candel Therapeutics, Inc. (CADL) — Stock Score Summary

Candel Therapeutics, Inc. (CADL) has a MoatMap StockRank of 67/100 based on Quality (34/100), Value (36/100), and Momentum (80/100) factor scores. The current signal is BUY. Candel Therapeutics is a highly speculative, clinical-stage biotech company with low quality metrics and no current revenues, failing our Terry Smith quality filter.

Candel Therapeutics, Inc. is a clinical-stage biotechnology company developing oncolytic viral immunotherapies for the treatment of various cancers. The company leverages a proprietary oncolytic viral platform designed to selectively destroy cancer cells and stimulate systemic anti-tumor immunity. Candel Therapeutics operates as a niche player in the immuno-oncology space, pursuing novel approaches for difficult-to-treat malignancies.

Key Financial Metrics

Price$8.80
Market Cap$593M
P/E (Forward)42.14
Price/Book4.92
Return on Equity-51.2%
Return on Invested Capital-31.0%
Debt/Equity35.70
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-38M

Candel Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Candel Therapeutics, Inc.’s (CADL) StockRank?
MoatMap’s StockRank for Candel Therapeutics, Inc. (CADL) is 67/100, with a Buy signal. It is a composite of Quality (34), Value (36), and Momentum (80) factor ranks across MoatMap’s 19,000+ stock universe.
Does Candel Therapeutics, Inc. have an economic moat?
Candel Therapeutics, Inc. (CADL) has a Quality factor score of 34/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Candel Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Candel Therapeutics, Inc. (CADL) is Buy, based on a StockRank of 67/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Candel Therapeutics, Inc. in?
Candel Therapeutics, Inc. (CADL) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksCADL deep dive reportAI ChampionsHow we score stocksSense-check another stock